|Published||Report Code||Available Format||Pages|
The global chronic pain treatment market valued $77.8 billion in 2019, and it is expected to grow at a 6.5% CAGR during the forecast period (2020–2030). The chronic pain treatment industry is booming due to the increasing government support for chronic pain treatment, growing geriatric population, and rising prevalence of chronic health conditions.
Due to the continuing COVID-19 pandemic, governments of numerous countries have restricted major human activities to reduce the spread rate of the disease. In such a scenario, chronic pain treatment drug and device manufacturers are operating through online websites, but are still facing a crisis, due to certain government regulations, which, in turn, is temporarily impeding the growth of the chronic pain treatment market.
In 2019, the drugs category dominated the chronic pain treatment market, and it is expected to maintain the same trend during the forecast period, primarily due to the increasing prevalence of lower back pain and migraine. Moreover, the consumption of drugs by the rising geriatric population is already high, and the high volume of surgical procedures performed on it also plays a pivotal role in the growth of the market.
Cancer is expected to be the fastest-growing indication category in the chronic pain treatment market during the forecast period. This growth is mainly attributed to the growing number of cancer cases due to the alarming environmental changes and adoption of a sedentary lifestyle.
The musculoskeletal category held the largest share in the chronic pain treatment market during the historical period (2014–2019), based on application. This was owing to the rapidly increasing prevalence of obesity, diabetes, and other chronic diseases. Moreover, the rising cases of musculoskeletal issues, along with the aging population, are expected to result in the steady growth of this category in the coming years.
In 2019, the direct mode of distribution held the larger share in the chronic pain treatment market, and it is expected to remain dominant during the forecast period. This is primarily due to the increasing focus on the distribution of pharmaceutical drugs and pain treatment devices via direct channels.
Hospitals are the largest end users of chronic pain treatment products. Pain treatment practices are more frequently performed in hospitals, particularly for post-surgical pain. Thus, with the growing number of surgical procedures around the world, hospitals are expected to continue as the leading end-user category in global chronic pain treatment market.
North America contributed the highest revenue to the chronic pain treatment market in the past, due to the high prevalence of chronic diseases and increasing awareness on the issue, huge number of chronic pain treatment clinics, and high adoption of non-opioid pain management options here. Moreover, with age, people fall prey to chronic illnesses, due to their reduced power of healing. In North America, 59.9 million people were aged 65 or above in 2019, with the number further expected to increase in the coming years.
The APAC chronic pain treatment market is expected to witness the fastest growth during the forecast period. The key factors responsible for the growth of the regional industry are the rapid rise in the working population and boom in the aging population. According to the United Nations (UN) ‘2019 statistics, 11.5% of China’s population and 28.0% of Japan’s population was 65 years or older. Moreover, the APAC market is moving toward the adoption of technologically advanced products, encouraged by different government organizations and their support for healthcare providers to be able to offer chronic pain management services.
The key trend being observed in the chronic pain treatment market is the rapid innovations in this field. One of the key advancements in this sector is the advent of the wearable technology for the treatment of chronic pain in old, as well as young patients. This technology is proving to be of great help for working people suffering from chronic illnesses. Moreover, several companies are focusing on the development of non-opioid pain therapies. Further, portable devices for chronic pain treatment have provided greater comfort to older patients. Therefore, the increasing number of innovations in pain management products and devices are fueling the growth of the industry.
Rising Government Support for Chronic Pain Treatment
Governments around the world are raising awareness on advanced pain treatment products and offering funding in this regard, which is helping in strengthening the industry outlook. For instance, the International Association for the Study of Pain (IASP)’s Developing Countries Project was executed from January to March 2018, for advancing pain education and practice in developing countries, by offering grants. These grants are intended to improve the scope and availability of essential education for clinicians involved in pain treatment and working in all disciplines, to encourage the development of innovative approaches.
Elderly people are more vulnerable to chronic diseases; therefore, the rise in the geriatric population is leading to the increasing demand for chronic pain treatment products. According to the World Population Ageing 2019 report, there were 703 million people aged 65 or above in the world that year, and more than half of them have multiple chronic health conditions. Therefore, the increasing geriatric population is driving the chronic pain treatment market.
The increasing prevalence of chronic diseases is a major healthcare burden in low-and middle-income countries. Cancer, neurological disorders, and orthopedic diseases are some of the chronic diseases which cause long-lasting pain. According to the WHO, approximately 70% of deaths from cancer occur in low- and middle-income countries. Moreover, lower back pain, migraine, neck pain, and joint pain lead to a high demand for pain treatment services, such as physiotherapy, psychological therapy, and neuroablation, across the world. Furthermore, several drugs manufactured by market players for the treatment of chronic diseases are under clinical trials, which are expected to be launched in the near future. Based on their clinical trials and results, these drugs are expected to generate significant revenue in the chronic pain treatment market.
|Base Year (2019) Market Size||$77.8 Billion|
|Forecast Period (2020-2030) CAGR||6.5%|
|Report Coverage||Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Impact of COVID-19, Companies’ Strategic Developments, Product Benchmarking, Company Profiling|
|Market Size by Segments||Product, Indication, Application, Distribution Channel, Region|
|Market Size of Geographies||U.S., Canada, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Sweden, Switzerland, Japan, China, India, Australia, South Korea, Brazil, Mexico, Saudi Arabia, South Africa|
|Secondary Sources and References (Partial List)||American Geriatrics Society, National Center for Biotechnology Information (NCBI), National Health Expenditure Accounts (NHEA), National Health Service (NHS), Organization for Economic Co-operation and Development (OECD), United Nations (UN)|
The global chronic pain treatment market is fragmented in nature, due to the presence of various market players, such as Johnson & Johnson, Novartis AG, Abbott Laboratories, Pfizer Inc., GlaxoSmithKline plc, and Eli Lilly and Company.
In recent years, market players have involved in multiple product launches, to gain a significant edge on the competition. For instance:
The chronic pain treatment market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.
Based on Product
Based on Indication
Based on Application
Based on Distribution Channel
Based on End User